Operating Income (Loss) in USD of Prelude Therapeutics Inc from Q3 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Prelude Therapeutics Inc quarterly/annual Operating Income (Loss) history and growth rate from Q3 2019 to Q3 2025.
  • Prelude Therapeutics Inc Operating Income (Loss) for the quarter ending September 30, 2025 was -$20.4M, a 40.6% increase year-over-year.
  • Prelude Therapeutics Inc Operating Income (Loss) for the twelve months ending September 30, 2025 was -$121M, a 15.5% increase year-over-year.
  • Prelude Therapeutics Inc annual Operating Income (Loss) for 2024 was -$140M, a 5.62% decline from 2023.
  • Prelude Therapeutics Inc annual Operating Income (Loss) for 2023 was -$132M, a 7.07% decline from 2022.
  • Prelude Therapeutics Inc annual Operating Income (Loss) for 2022 was -$124M, a 8.62% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Prelude Therapeutics Inc Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$121M -$20.4M +$14M +40.6% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 -$135M -$32.2M +$4.97M +13.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 -$140M -$34.6M -$263K -0.77% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q4 2024 -$140M -$33.8M +$3.55M +9.49% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-10
Q3 2024 -$143M -$34.4M -$991K -2.97% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 -$142M -$37.2M -$4.77M -14.7% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 -$138M -$34.3M -$5.23M -18% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q4 2023 -$132M -$37.4M -$3.99M -12% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-10
Q3 2023 -$128M -$33.4M -$2.98M -9.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$125M -$32.4M -$2.94M -9.97% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$122M -$29.1M +$1.17M +3.87% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$124M -$33.4M -$375K -1.14% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 -$123M -$30.4M +$430K +1.39% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$124M -$29.5M -$1.54M -5.51% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$122M -$30.3M -$8.32M -37.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$114M -$33M -$13.6M -69.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$100M -$30.8M -$12.7M -70% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$87.5M -$27.9M -$16.5M -144% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$71M -$22M -$12.2M -126% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$58.8M -$19.4M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$18.1M -$11.3M -164% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$11.4M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$9.74M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q3 2019 -$6.88M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10

Prelude Therapeutics Inc Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$140M -$7.44M -5.62% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-10
2023 -$132M -$8.74M -7.07% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-10
2022 -$124M -$9.81M -8.62% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-15
2021 -$114M -$55M -93.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 -$58.8M -$30.7M -109% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$28.1M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.